<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177552</url>
  </required_header>
  <id_info>
    <org_study_id>01052014</org_study_id>
    <secondary_id>2014-000127-24</secondary_id>
    <nct_id>NCT02177552</nct_id>
  </id_info>
  <brief_title>Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma</brief_title>
  <acronym>SEED</acronym>
  <official_title>Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma - Carboplatin, Docetaxel and Capecitabine (CTX) or Epirubicin, Oxaliplatin and Capecitabine: a Randomised Phase 2 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the effects of treatment with carboplatin,
      docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants alive one year after randomisation</measure>
    <time_frame>Three and a half years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression or death due to any cause</measure>
    <time_frame>Three and a half years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with grade 3 and 4 toxicities caused by treatments</measure>
    <time_frame>Day 1 of every cycle and 30 days after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until death due to any cause</measure>
    <time_frame>Three and a half years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality-of-life</measure>
    <time_frame>Three and a half years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who have carboplatin, docetaxel and capecitabine re-induced</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Registration of further lines of therapy</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of cmet by immunohistochemistry</measure>
    <time_frame>Three and a half years</time_frame>
    <description>Analysis of archived tumour tissue (primary biopsy, previous surgical resection specimen if available) and metastatic tumour tissue for consenting subjects.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Experimental chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Experimental chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Experimental chemotherapy</arm_group_label>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Standard chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients with histologically verified, unresectable or metastatic, HER2-negative,
             adenocarcinoma of the esophagus or stomach

          -  Men or women less than 80 years of age

          -  Performance status 0 or 1

          -  Life expectancy &gt;12 weeks

          -  Adequate organ-function

          -  Written informed consent

        Key Exclusion Criteria:

          -  Prior chemotherapy for adenocarcinoma of the esophagus or stomach if the
             chemotherapy-free interval is less than 6 months

          -  Progression on first-line chemotherapy for unresectable or metastatic adenocarcinoma
             of the esophagus or stomach

          -  Chemotherapy with epirubicin, oxaliplatin, carboplatin, cisplatin or docetaxel less
             than 6 months before study entry

          -  Prior cumulative dose of &gt;300 mg/m2 of epirubicin

          -  Grade â‰¥ 2 side-effects from previous chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter C Petersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Finsen Center, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter C Petersen, MD</last_name>
    <email>peter.c.petersen@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lene Baeksgaard, MD</last_name>
    <email>lene.baeksgaard.jensen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Finsen Center, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter C Petersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lene Baeksgaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Peter Clausager Petersen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

